Stokes & Hubbell Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Stokes & Hubbell Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.8M	Buy	37,752 +8	+0%	+$399	0.38%	56
2018 Q4	$1.96M	Sell	37,744 -704	-2%	-$37.8K	0.44%	49
2018 Q3	$2.39M	Buy	38,448 +2,954	+8%	+$175K	0.49%	49
2018 Q2	$1.96M	Sell	35,494 -2,609	-7%	-$141K	0.44%	50
2018 Q1	$2.41M	Buy	38,103 +87	+0.2%	+$5.6K	0.56%	47
2017 Q4	$2.33M	Buy	38,016 +158	+0.4%	+$9.88K	0.56%	46
2017 Q3	$2.41M	Buy	37,858 +21,926	+138%	+$1.28M	0.62%	44
2017 Q2	$888K	Buy	15,932 +2,632	+20%	+$143K	0.27%	58
2017 Q1	$723K	Buy	13,300 +206	+2%	+$11.3K	0.25%	60
2016 Q4	$765K	Buy	13,094 +2,855	+28%	+$156K	0.3%	54
2016 Q3	$552K	Buy	10,239 +4	+0%	+$257	0.23%	61
2016 Q2	$753K	Buy	10,235 +953	+10%	+$67.3K	0.32%	50
2016 Q1	$593K	Buy	9,282 +1,049	+13%	+$66.2K	0.27%	49
2015 Q4	$566K	Buy	8,233 +3	+0%	+$198	0.31%	49
2015 Q3	$487K	Buy	+8,230	New	+$522K	0.3%	48

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Stokes & Hubbell Capital Management's BMY Position: Q1 2019 in Review

Stokes & Hubbell Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.02% in Q1 2019, buying an estimated $399 and bringing the position to 37,752 shares worth $1.8M. The position accounts for 0.38% of the portfolio, ranked #56.

Stokes & Hubbell Capital Management first reported a position in BMY in Q3 2015 and has held it in 15 quarters since. The position peaked at $2.41M in Q3 2017. 1,814 funds tracked by Wall St. Rank hold BMY as of Q1 2019.

Stokes & Hubbell Capital Management held 37,752 shares of Bristol-Myers Squibb worth $1.8M as of Q1 2019.
Stokes & Hubbell Capital Management bought 8 Bristol-Myers Squibb shares in Q1 2019, an estimated $399.
Bristol-Myers Squibb made up 0.38% of Stokes & Hubbell Capital Management's portfolio in Q1 2019, its #56 holding.
Stokes & Hubbell Capital Management first reported a position in Bristol-Myers Squibb in Q3 2015 and has held it in 15 quarters since.
Stokes & Hubbell Capital Management's Bristol-Myers Squibb position peaked at $2.41M in Q3 2017.
1,814 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2019.

Based on Stokes & Hubbell Capital Management's 13F filing for Q1 2019, filed 24 Apr 2019.